An interview with J. Jaime Caro.
Research conducted by James Caro, MDCM, focuses on the economic costs of stroke in patients with atrial fibrillation (AF), and how much can be saved by optimizing anticoagulation in these patients. His research will have practical implications not only for researchers but also the clinicians and decision makers within managed care settings who must allocate resources for competing prevention programs. A panelist at the roundtable organized by The American Journal of Managed Care, Dr. Caro recently reported preliminary results from his economic analyses at the 2004 World Stroke Congress in Vancouver, BC. He spoke with an editor from AJMC about those studies.
Caro
J Jaime
JJ
D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics; D017281:Cost of Illness; D017048:Health Care Costs; D006801:Humans; D008329:Managed Care Programs / Q000191:economics; D006278:Medicare; D020521:Stroke / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin